Endogenous interleukin-1α promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 6, 2007, Pages

  Schultz, Kelly ^a   Murthy, Vanishree ^a   Tatro, Jeffrey B ^a   Beasley, Debbie ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cell proliferation; Monocyte chemoattractant protein 1; Type I interleukin 1 receptor

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA SYNTHESIS; HUMAN; HUMAN CELL; INFLAMMATION; KNOCKOUT GENE; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

AUTOCRINE COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CORONARY VESSELS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, INTERLEUKIN-1 TYPE I; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERUM; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TRANSFECTION;

EID: 34447525220     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00700.2006     Document Type: Article

References (38)

1. Andres V, Castro C. Antiproliferative strategies for the treatment of vascular proliferative disease. Curr Vasc Pharmacol 1: 85-98, 2003.
2. Bailly S, Ferrua B, Fay M, Gougerot-Pocidalo MA. Paraformaldehyde fixation of LPS-stimulated human monocytes: technical parameters permitting the study of membrane IL-1 activity. Eur Cytokine Netw 1: 47-51, 1990.
3. Beasley D, Cooper A. Constitutive expression of interleukin-1α precursor promotes human vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol 276: H901-H912, 1999.
4. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10: 416-421, 2004.
5. Brody JI, Pickering NJ, Capuzzi DM, Fink GB, Can CA, Gomez F. Interleukin-1 alpha as a factor in occlusive vascular disease. Am J Clin Pathol 97: 8-13, 1992.
6. Carruth L, Demczuk S, Mizel S. Involvement of a calpain-like protease in the processing of the murine interleukin 1α precursor. J Biol Chem 266: 12162-12167, 1991.
7. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 95: 858-866, 2004.
8. Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 110: 1678-1685, 2004.
9. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87: 5134-5138, 1990.
10. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147, 1996.
11. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil SV, Espevik T, Finlay BB, Wright SD. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 176: 1665-1671, 1992.
12. Huber M, Beuscher HU, Rohwer P, Kurrle R, Rollinghoff M, Lohoff M. Costimulation via TCR and IL-1 receptor reveals a novel IL-1alphamediated autocrine pathway of Th2 cell proliferation. J Immunol 160: 4242-4247, 1998.
13. Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, Kusuhara M, Nishida Y, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation 108: 516-518, 2003.
14. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462, 2005.
15. Kaplanski G, Farnarier C, Kaplanski S, Porat R, Shapiro L, Bongrand P, Dinarello C. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood 84: 1-7, 1994.
16. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 103: 1253-1260, 1999.
17. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 81: 487-498, 1988.
18. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 66: 583-593, 2005.
19. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101: 10679-10684, 2004.
20. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol 59: 232-239, 2006.
21. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 138: 951-1014, 1991.
22. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88: 1121-1127, 1991.
23. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem 279: 16452-16462, 2004.
24. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 102: 1697-1702, 2000.
25. Sasu S, Cooper AL, Beasley D. Juxtacrine effects of IL-1α precursor promote iNOS expression in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 280: H1615-H1623, 2001.
26. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 89: 244-250, 2001.
27. Schaub FJ, Han DK, Liles WC, Adams LD, Coats SA, Ramachandran RK, Seifert RA, Schwartz SM, Bowen-Pope DF. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 6: 790-796, 2000.
28. Schaub FJ, Liles WC, Ferri N, Sayson K, Seifert RA, Bowen-Pope DF. Fas and Fas-associated death domain protein regulate monocyte chemoattractant protein-1 expression by human smooth muscle cells through caspase- and calpain-dependent release of interleukin-1alpha. Circ Res 93: 515-522, 2003.
29. Schober A, Zernecke A, Liehn EA, von Hundelshausen P, Knarren S, Kuziel WA, Weber C. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res 95: 1125-1133, 2004.
30. Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 66: 162-169, 2005.
31. Schultz K, Fanburg BL, Beasley D. Hypoxia and hypoxia-inducible factor-1α promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 290: H2528-H2534, 2006.
32. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JPG, Smeets MB, Quax PHA, Lim SK, Borst C, Pasterkamp G, de Kleijn DPV. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106: 1985-1990, 2002.
33. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet 347: 305-307, 1996.
34. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, Voronov E, Dinarello CA, Apte RN. The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 101: 2434-2439, 2004.
35. Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T. Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. J Biol Chem 268: 22100 -22104, 1993.
36. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol 289: H1069-H1076, 2005.
37. Yang X, Coriolan D, Schultz K, Golenbock DT, Beasley D. Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 25: 2308-2314, 2005.
38. Yang X, Murthy V, Schultz K, Tatro JB, Fitzgerald KA, Beasley D. Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 291: H2334-H2343, 2006.